DOCSLIB.ORG

BQI Icare HIV/AIDS

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
BQI Icare HIV/AIDS RESOURCE AND PATIENT MANAGEMENT SYSTEM iCare Population Management GUI (BQI) HIV/AIDS Management User Manual Version 2.6 July 2017 Office of Information Technology (OIT) Division of Information Technology iCare Population Management GUI (BQI) Version 2.6 Table of Contents 1.0 Introduction ......................................................................................................... 1 1.1 Key Functional Features .......................................................................... 1 1.2 Sensitive Patient Data ............................................................................. 2 2.0 Patient Management ........................................................................................... 3 2.1 Data Specifically Related to HIV/AIDS ..................................................... 3 2.2 Search for and View a Patient Record ..................................................... 6 2.2.1 Using a Panel ........................................................................................ 6 2.2.2 Using Quick Search ............................................................................... 7 2.3 Displaying Care Management as Default Tab ......................................... 8 2.4 Add/Edit Care Management Data ............................................................ 8 2.4.1 Entering Data on the General Area ....................................................... 9 2.4.2 Entering Data on the Partner Notification Area .................................... 11 2.4.3 Entering Data on the Antiretroviral Status Area ................................... 12 2.4.4 Completing the State Notifications Area .............................................. 14 2.4.5 Completing the Data Entry Process ..................................................... 15 2.5 HIV/AIDS Diagnostic Tags ..................................................................... 17 2.5.1 Accept/Do Not Accept Proposed HIV/AIDS Diagnostic Tab ................ 17 2.5.2 Change a Diagnostic Tag to Proposed ................................................ 18 2.5.3 Manually Add an HIV/AIDS Diagnostic Tag ......................................... 19 2.6 HMS Patient Care Supplement .............................................................. 20 2.6.1 Search Methods for the Supplement ................................................... 21 2.6.2 Using the Controls on the Report ........................................................ 22 2.7 Related Conditions ................................................................................ 22 2.7.1 Opportunistic Infections/AIDS Defining Illnesses ................................. 22 2.7.2 AIDS Defining Illnesses ....................................................................... 26 2.8 HIV/AIDS-Related Reminders ............................................................... 27 3.0 Panel Management ........................................................................................... 30 3.1 Using the No Predefinition/Population Search ....................................... 31 3.2 Using the Patients Assigned To Search ................................................ 31 3.3 Using the QMAN Template Search........................................................ 31 3.4 Using the RPMS Register Parameters Search ...................................... 31 3.5 Patients with HIV/AIDS Diagnostic Tag Search ..................................... 32 3.6 Patients with AIDS or HIV on Problem List Search ................................ 32 3.7 Patients with AIDS or HIV Reminder Search ......................................... 32 3.8 Patients Who Visit HIV/AIDS Clinic Search ........................................... 33 4.0 Reports .............................................................................................................. 34 4.1 HMS Patient Care Supplement .............................................................. 34 4.2 State Surveillance Report (SSR) ........................................................... 34 4.3 Quality of Care (QOC) Report ............................................................... 36 5.0 HIV/AIDS Community Alert .............................................................................. 40 HIV/AIDS Management User Manual Table of Contents July 2017 ii iCare Population Management GUI (BQI) Version 2.6 6.0 Taxonomy Management ................................................................................... 41 6.1 What Is a Taxonomy .............................................................................. 41 6.2 Taxonomy Nomenclature ....................................................................... 41 6.3 Software-Defined (Hard-coded) Taxonomies ........................................ 42 6.4 Site Populated Taxonomies ................................................................... 42 6.4.1 Lab Test Taxonomies .......................................................................... 43 6.4.2 Medication Taxonomies ....................................................................... 48 6.5 View a Taxonomy .................................................................................. 51 6.6 View a Report of All Taxonomies ........................................................... 53 6.7 Identify Empty Taxonomies ................................................................... 53 6.8 Add a Member to a Site-Populated Taxonomy ...................................... 54 6.9 Remove a Member from a Site-Populated Taxonomy ........................... 58 7.0 Using the HIV/AIDS Glossary .......................................................................... 61 Appendix A: Definitions and Taxonomies Content .............................................. 64 A.1 Opportunistic Infections ......................................................................... 64 A.2 AIDS Defining Illnesses ......................................................................... 86 A.3 HIV/AIDS Definitions, Codes, Taxonomies, Attributes ......................... 110 Appendix B: HIV/AIDS-Related Reminders – Logic and Tooltip Text ............... 120 B.1 CD4 Test ............................................................................................. 120 B.1.1 Description Fields Text ...................................................................... 120 B.1.2 Tooltip Text ........................................................................................ 120 B.2 Chlamydia Test .................................................................................... 120 B.2.1 Description Field Text ........................................................................ 120 B.2.2 Tooltip Text ........................................................................................ 122 B.3 HMS Dental Exam ............................................................................... 123 B.3.1 Description Field Text ........................................................................ 123 B.3.2 Tooltip Text ........................................................................................ 123 B.4 HMS Eye Exam ................................................................................... 123 B.4.1 Description Field Text ........................................................................ 123 B.4.2 Tooltip Text ........................................................................................ 124 B.5 Family Planning Education .................................................................. 124 B.5.1 Description Field Text ........................................................................ 124 B.5.2 Tooltip Text ........................................................................................ 125 B.6 Syphilis (FTA-ABS) Test ...................................................................... 125 B.6.1 Description Field Text ........................................................................ 125 B.6.2 Tooltip Text ........................................................................................ 126 B.7 Gonorrhea Test.................................................................................... 126 B.7.1 Description Field Text ........................................................................ 126 B.7.2 Tooltip Text ........................................................................................ 128 B.8 Hepatitis A IZ ....................................................................................... 128 B.8.1 Description Field Text ........................................................................ 128 B.8.2 Tooltip Text ........................................................................................ 129 B.9 Hepatitis B IZ ....................................................................................... 129 B.9.1 Description Field Text ........................................................................ 129 B.9.2 Tooltip Text ........................................................................................ 129 HIV/AIDS Management User Manual Table of Contents July 2017 iii iCare Population Management GUI (BQI) Version 2.6 B.10 Hepatitis B Retest ................................................................................ 130 B.10.1 Description Field Text ........................................................................ 130 B.10.2 Tooltip Text ........................................................................................ 130 B.11 Hepatitis B Test ..................................................................................
Load more

Recommended publications
  • ICD10 Diagnoses FY2018 AHD.Com
    ICD10 Diagnoses FY2018 AHD.com A020 Salmonella enteritis A5217 General paresis B372 Candidiasis of skin and nail A040 Enteropathogenic Escherichia coli A523 Neurosyphilis, unspecified B373 Candidiasis of vulva and vagina infection A528 Late syphilis, latent B3741 Candidal cystitis and urethritis A044 Other intestinal Escherichia coli A530 Latent syphilis, unspecified as early or B3749 Other urogenital candidiasis infections late B376 Candidal endocarditis A045 Campylobacter enteritis A539 Syphilis, unspecified B377 Candidal sepsis A046 Enteritis due to Yersinia enterocolitica A599 Trichomoniasis, unspecified B3781 Candidal esophagitis A047 Enterocolitis due to Clostridium difficile A6000 Herpesviral infection of urogenital B3789 Other sites of candidiasis A048 Other specified bacterial intestinal system, unspecified B379 Candidiasis, unspecified infections A6002 Herpesviral infection of other male B380 Acute pulmonary coccidioidomycosis A049 Bacterial intestinal infection, genital organs B381 Chronic pulmonary coccidioidomycosis unspecified A630 Anogenital (venereal) warts B382 Pulmonary coccidioidomycosis, A059 Bacterial foodborne intoxication, A6920 Lyme disease, unspecified unspecified unspecified A7740 Ehrlichiosis, unspecified B387 Disseminated coccidioidomycosis A080 Rotaviral enteritis A7749 Other ehrlichiosis B389 Coccidioidomycosis, unspecified A0811 Acute gastroenteropathy due to A879 Viral meningitis, unspecified B399 Histoplasmosis, unspecified Norwalk agent A938 Other specified arthropod-borne viral B440 Invasive pulmonary
    [Show full text]
  • Known Infectious Causes of Vasculitis in Man
    PATHOGENESIS Known infectious causes of vasculitis in man STANLEY J. NAIDES, MD n array of pathogens is known to cause vasculi- and our ability to intervene in disease processes, have ren- tis in man.1,2 For several of these agents, vas- dered some causes of vasculitis far less common. culitis is the major manifestation of disease. The Amajority, however, typically present as infec- ■ VIRAL CAUSES OF VASCULITIS tious processes in which vasculitis is an occasional mani- Our knowledge of viral pathogenesis has exploded in the festation of disease. For many, vasculitis may be a compo- last quarter of the twentieth century, accelerated in large nent of disease pathogenesis but is not a prominent feature part by epidemics of “emerging” viral diseases. Hepatitis C of the clinical presentation. The various agents—viruses, virus, discovered in 1989, has worldwide prevalence.3 The bacteria, and fungi—share a common target, blood vessels. 10- to 20-year latent period before hepatic or rheumatic The involvement of vessels may be direct, with vascular manifestations of disease explains the increasing number structures serving as targets. Many infectious pathogens of cases of hepatitis C virus–mediated vasculitis currently have tissue tropism that includes endothelium. Other being seen in the United States following the epidemic of agents may bind to the vessel wall because the vascular en- new infections in the 1980s.4 Prior to the discovery and dothelium expresses specific receptors for the pathogen or characterization of hepatitis C virus in the late 1980s, the another moiety with which the pathogen travels. Even triad of arthritis, palpable purpura, and type II cryoglobu- when the agent does not enter the endothelial cell, the im- linemia was given the sobriquet “essential mixed cryo- mune response to the agent may be focused at the vessel globulinemia” and considered an idiopathic vasculitis.
    [Show full text]
  • Educational Achievement and Economic Self-Sufficiency in Adults After Childhood Bacterial Meningitis
    1 Supplementary Online Content Roed C, Omland LH, Skinhoj P, Rothman KJ, Sorensen HT, Obel N. Educational achievement and economic self-sufficiency in adults after childhood bacterial meningitis. JAMA. doi:10.1001/jama.2013.3792 Appendix 1. Description of Registries Appendix 2. Diagnosis Codes for Intrauterine and Birth Asphyxia or Chromosomal Abnormalities Appendix 3. Diagnosis Codes for Meningococcal, Pneumococcal, Or H influenzae Meningitis Appendix 4. Diagnosis Codes for Neuroinfections Other Than Bacterial Meningitis eTable 1. Number of Events in the Study Population and Total Observation Time eTable 2. Estimated Prevalence at Age 35 of Vocational Education, High School, Higher Education, Economic Self‐sufficiency and Disability pension Among Meningitis Patients, Members of the Population Comparison Cohorts, and Their Siblings Without Neonatal Morbidity eFigure 1. Cumulative Incidence of Having Been Economically Self‐sufficient for a Year and of Receiving Disability Pension in the Meningococcal, Pneumococcal and H. influenzae Meningitis Patients (Black), Members of the Population Comparison Cohort (Red), Full Siblings of Patients (Green) and Siblings of Members of the Population Comparison Cohort (Blue) eFigure 2. Cumulative Incidence of Vocational Education, High School and Higher Education for Meningococcal, Pneumococcal and H. influenzae Meningitis Patients (Black), Members of the Population Comparison Cohort (Red), Full Siblings of Patients (Green) and Full Siblings of Members of the Population Comparison Cohort (Blue) Born Before 1980 eFigure 3. Cumulative Incidence of Vocational Education, High School and Higher Education for Meningococcal, Pneumococcal and H. influenzae Meningitis Patients (Black), Members of the Population Comparison Cohort (Red), Full Siblings of Patients (Green) and Full Siblings of Members of the Population Comparison Cohort (Blue) Born After 1980 This supplementary material has been provided by the authors to give readers additional information about their work.
    [Show full text]
  • Identification of Microorganisms Using Nucleic Acid Probes
    Identification of Microorganisms Using Page 1 of 45 Nucleic Acid Probes Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Identification of Microorganisms Using Nucleic Acid Probes See Also: Influenza Virus Diagnostic Testing and Treatment in the Outpatient Setting Professional Institutional Original Effective Date: July 8, 2008 Original Effective Date: July 16, 2009 Revision Date(s): June 16, 2009; Revision Date(s): March 1, 2012; March 1, 2012; June 5, 2012; June 5, 2012; November 19, 2012; November 19, 2012; January 15, 2013; January 15, 2013; November 12, 2013 November 12, 2013 Current Effective Date: November 12, 2013 Current Effective Date: November 12, 2013 State and Federal mandates and health plan member contract language, including specific provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. To verify a member's benefits, contact Blue Cross and Blue Shield of Kansas Customer Service. The BCBSKS Medical Policies contained herein are for informational purposes and apply only to members who have health insurance through BCBSKS or who are covered by a self-insured group plan administered by BCBSKS. Medical Policy for FEP members is subject to FEP medical policy which may differ from BCBSKS Medical Policy. The medical policies do not constitute medical advice or medical care. Treating health care providers are independent contractors and are neither employees nor agents of Blue Cross and Blue Shield of Kansas and are solely responsible for diagnosis, treatment and medical advice. If your patient is covered under a different Blue Cross and Blue Shield plan, please refer to the Medical Policies of that plan.
    [Show full text]
  • Syphilis As Seen by a Hospital Physician
    284 Prof. Monro?Syphilis as seen by a Hospital Physician. SYPHILIS AS SEEN BY A HOSPITAL PHYSICIAN* By T. K. MONRO, M.A., M.D., Professor of Medicine, University of Glasgow. \ " / Mr. President and Gentlemen,?I thank you heartily for the honour you have done me in inviting me to be Honorary President of this Faculty for the session which is now opening. I was duly informed by Dr. Wardlaw that my principal duty as incumbent of this honourable office was to deliver an address to the Faculty, and as his invitation reached me while I was on holiday, with other objects in view, I had time to contemplate the responsibility I had undertaken, and to consider how I was to face it. In getting over the usual initial difficulty as to the choice of a subject, some assistance was afforded me by the President's instruction that the address ought to be one for the general practitioner. Quite a number of subjects would be appropriate from this point of view. I should have been glad to say some- thing on oral sepsis, a condition often spoken of, and no doubt often wrongly blamed, but also apt to be overlooked. Dentists do not always realise how completely one may be misled by the absence of subjective and objective evidence; so that even an experienced man may pass as innocuous a tooth which subse- quent extraction shows to have disease at its root. Medical men sometimes make a mistake in the opposite direction, by insisting, without sufficient justification, on the removal of teeth, e.g., in epileptiform neuralgia.
    [Show full text]
  • Neuropsychological Testing
    Medical Coverage Policy Effective Date ............................................. 8/15/2021 Next Review Date ....................................... 8/15/2022 Coverage Policy Number .................................. 0258 Neuropsychological Testing Table of Contents Related Coverage Resources Overview .............................................................. 1 Attention-Deficit/Hyperactivity Disorder: Assessment Coverage Policy ................................................... 1 and Treatment General Background ............................................ 2 Autism Spectrum Disorder/Pervasive Developmental Medicare Coverage Determinations .................. 15 Disorders: Assessment and Treatment Coding/Billing Information .................................. 16 Cognitive Rehabilitation Lyme Disease Treatment— Antibiotic Treatment References ........................................................ 28 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary
    [Show full text]
  • A Review of Primary Vasculitis Mimickers Based on the Chapel Hill Consensus Classification
    Hindawi International Journal of Rheumatology Volume 2020, Article ID 8392542, 11 pages https://doi.org/10.1155/2020/8392542 Review Article A Review of Primary Vasculitis Mimickers Based on the Chapel Hill Consensus Classification Farah Zarka ,1 Charles Veillette ,1 and Jean-Paul Makhzoum 2 1Hôpital du Sacré-Cœur de Montreal, University of Montreal, Canada 2Vasculitis Clinic, Department of Internal Medicine, Hôpital du Sacré-Coeur de Montreal, University of Montreal, Canada Correspondence should be addressed to Jean-Paul Makhzoum; [email protected] Received 10 July 2019; Accepted 7 January 2020; Published 18 February 2020 Academic Editor: Charles J. Malemud Copyright © 2020 Farah Zarka et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Primary systemic vasculitides are rare diseases that may manifest similarly to more commonly encountered conditions. Depending on the size of the vessel affected (large vessel, medium vessel, or small vessel), different vasculitis mimics must be considered. Establishing the right diagnosis of a vasculitis mimic will prevent unnecessary immunosuppressive therapy. 1. Introduction 2. Large-Vessel Vasculitis Mimics Vasculitides are rare heterogenous diseases that affect vessel Large-vessel vasculitis (LVV) is an inflammatory vascu- walls as the main site of inflammation. Organs affected vary lopathy affecting large arteries; giant cell arteritis (GCA) depending on the type and size of blood vessels involved and Takayasu’s arteritis (TAK) are the two main docu- [1]. Autoimmune vasculitis can be primary (idiopathic) or mented variants, each with their own characteristic fea- secondary to an underlying disease.
    [Show full text]
  • List of Codes Used to Identify Measures Reported in the QDFC
    List of Codes Used to Identify Measures Reported in the Quarterly Dialysis Facility Compare Reports July 2018 List of Codes Used to Identify Measures Reported in the Quarterly Dialysis Facility Compare Reports Table of Contents Table 1a: Transfusion Summary for Medicare Dialysis Patients, Codes Used for Exclusions 3 CARCINOMA 3 COAGULATION 5 HEAD/NECK CANCER 5 HEMOLYTIC OR APLASTIC ANEMIA 9 LEUKEMIA 11 LYMPHOMA 15 METASTATIC 27 MYELOMA, ETC. 29 OTHER CANCER 30 SICKLE CELL 34 SOLID ORGAN CANCER 34 Table 1b: Transfusion Summary for Medicare Dialysis Patients, Codes Used to Identify Transfusion Events .................................................................................................................. 45 REVENUE CENTER CODES 45 PROCEDURE CODES 45 VALUE CODES 46 HCPCS CODE 46 Table 2a: Vascular Access Measures (SFR and Long-Term Catheter) for Medicare Dialysis Patients Based on Medicare Claims, Codes Used for Exclusions ........................................... 46 Produced by The University of Michigan Kidney Epidemiology and Cost Center Page 1 of 135 List of Codes Used to Identify Measures Reported in the Quarterly Dialysis Facility Compare Reports July 2018 COMA 46 END STAGE LIVER DISEASE 48 METASTATIC CANCER 48 Table 2b: Standardized Fistulae Rate (SFR) for Medicare Dialysis Patients Based on Medicare Claims, Codes Used for Prevalent Comorbidities Adjusted in Model .................................... 50 ANEMIA 50 CORONARY ARTERY DISEASE 52 CONGESTIVE HEART FAILURE 55 CEREBROVASCULAR DISEASE 56 CHRONIC OBSTRUCTIVE PULMONARY DISEASE 68 DIABETES 69 DRUG DEPENDENCE 79 INFECTIONS (NON-VASCULAR ACCESS-RELATED): 93 PERIPHERAL VASCULAR DISEASE (INCLUDES ARTERIAL, VENOUS AND NONSPECIFIC DISEASES) 124 Table 3: Dialysis Adequacy ...................................................................................................
    [Show full text]
  • Academy of Medical Sciences of Ukraine L. V. Gromashevskiy
    Academy of Medical Sciences of Ukraine L. V. Gromashevskiy Institute of Epidemiology and Infektious Diseases Panasiuk Olena Leonidivna ETHIOPATHOGENETIC THERAPY OF HERPES VIRUS INFECTION WITH THE USE OF PROTEFLAZID 14.01.13 — Infektious Diseases Kyiv — 2007 TABLE OF CONTENTS LIST OF ABBREVIATIONS USED INTRODUCTION CHAPTER 1 PRESSING ISSUES OF TREATMENT OF HERPES VIRUS INFECTIONS 1.2. Main principles of treatment of patients with herpes virus infections CHAPTER 2 MATERIALS AND STUDY METHODS 2.1. Characteristic of examined patients 2.2. Characteristic of study drug and treatment methods 2.3. Study design 2.3.1. Subjects enrollment and discontinuation criteria 2.3.2. Principles and algorithm of subjects grouping 2.3.3. Assessment of therapy efficacy 2.4. Study methods 2.4.1. Clinical method 2.4.2. Special study methods 2.4.3. Statistical method CHAPTER 3 ETHIOPATHOGENETIC THERAPY OF HERPES VIRUS INFECTION WITH THE USE OF PROTEFLAZID 3.1. Clinical efficacy of Proteflazid 3.2. Adverse effects of therapy with Proteflazid 3.3. Interferon inducing and immunomodulatory activity of Proteflazid in subjects with herpes virus infection 3.3.1. Immunomodulatory activity of Proteflazid 3.3.2. Interferon inducing properties of Proteflazid CHAPTER 4 LONG-TERM RESULTS OF TREATMENT OF HERPES VIRUS INFECTION 4.1. Anti-relapse efficacy of Proteflazid CONCLUSIONS PRACTICAL GUIDELINES REFERENCES List of abbreviations used NK (CD16) — natural killer cells NSE — neurospecific enolase ME — meningoencerebritis ANAD — acyclic nucleoside antiviral drugs AB — antibody
    [Show full text]
  • SNF Mobility Model: ICD-10 HCC Crosswalk, V. 3.0.1
    The mapping below corresponds to NQF #2634 and NQF #2636. HCC # ICD-10 Code ICD-10 Code Category This is a filter ceThis is a filter cellThis is a filter cell 3 A0101 Typhoid meningitis 3 A0221 Salmonella meningitis 3 A066 Amebic brain abscess 3 A170 Tuberculous meningitis 3 A171 Meningeal tuberculoma 3 A1781 Tuberculoma of brain and spinal cord 3 A1782 Tuberculous meningoencephalitis 3 A1783 Tuberculous neuritis 3 A1789 Other tuberculosis of nervous system 3 A179 Tuberculosis of nervous system, unspecified 3 A203 Plague meningitis 3 A2781 Aseptic meningitis in leptospirosis 3 A3211 Listerial meningitis 3 A3212 Listerial meningoencephalitis 3 A34 Obstetrical tetanus 3 A35 Other tetanus 3 A390 Meningococcal meningitis 3 A3981 Meningococcal encephalitis 3 A4281 Actinomycotic meningitis 3 A4282 Actinomycotic encephalitis 3 A5040 Late congenital neurosyphilis, unspecified 3 A5041 Late congenital syphilitic meningitis 3 A5042 Late congenital syphilitic encephalitis 3 A5043 Late congenital syphilitic polyneuropathy 3 A5044 Late congenital syphilitic optic nerve atrophy 3 A5045 Juvenile general paresis 3 A5049 Other late congenital neurosyphilis 3 A5141 Secondary syphilitic meningitis 3 A5210 Symptomatic neurosyphilis, unspecified 3 A5211 Tabes dorsalis 3 A5212 Other cerebrospinal syphilis 3 A5213 Late syphilitic meningitis 3 A5214 Late syphilitic encephalitis 3 A5215 Late syphilitic neuropathy 3 A5216 Charcot's arthropathy (tabetic) 3 A5217 General paresis 3 A5219 Other symptomatic neurosyphilis 3 A522 Asymptomatic neurosyphilis 3 A523 Neurosyphilis,
    [Show full text]
  • 30-Year Trends in Admission
    Iro, M. A., Sadarangani, M., Goldacre, R., Nickless, A., Pollard, A., & Goldacre, M. J. (2017). 30-year trends in admission rates for encephalitis in children in England and effect of improved diagnostics and measles-mumps-rubella vaccination: a population-based observational study. The Lancet Infectious Diseases. https://doi.org/10.1016/S1473-3099(17)30114-7 Peer reviewed version License (if available): CC BY-NC-ND Link to published version (if available): 10.1016/S1473-3099(17)30114-7 Link to publication record in Explore Bristol Research PDF-document This is the accepted author manuscript (AAM). The final published version (version of record) is available online via Elsevier at https://doi.org/10.1016/S1473-3099(17)30114-7 . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/ Thirty-year trends in admission rates for childhood encephalitis in England and impact of improved diagnostics and measles and mumps vaccination– a population based observational study Mildred A Iro (MBBS) 1, Manish Sadarangani (DPhil) 1,2, Raphael Goldacre (MSc)3, Alecia Nickless (MSc) 4, Prof Andrew J Pollard* (FMedSci) 1, Prof Michael J Goldacre* (FFPH) 3 1Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical
    [Show full text]
  • Supplementary Appendix
    Supplementary appendix Sipilä PN, Heikkilä N, Lindbohm JV, Hakulinen C, Vahtera J, Elovainio M, Suominen S, Väänänen A, Koskinen A, Nyberg ST, Pentti J, Strandberg TE, Kivimäki M. Hospital-treated infectious diseases and the risk of incident dementia: multicohort study with replication in the UK Biobank CONTENTS eFigure 1. Selection of participants in the study............................................................................... 2 eMethods 1. Study cohorts and data collection ................................................................................ 3 The Finnish Public Sector study (FPS)......................................................................................... 3 The Health and Social Support study (HeSSup) ........................................................................... 4 The Still Working study (STW) ................................................................................................... 5 The UK Biobank ......................................................................................................................... 5 eMethods 2. Proportionality of hazards ........................................................................................... 7 eFigure 2. Visualisation of hazard ratios over time using exponentiated scaled Schoenfeld residuals ....................................................................................................................................................... 8 eFigure 3. Dementia follow-up .....................................................................................................
    [Show full text]